Drug Profile
Dinutuximab beta - Children's Cancer Research Institute/EUSA Pharma
Alternative Names: APN 311; ch14.18/CHO; ISQETTE; QARZIBA; QarzibaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Children's Cancer Research Institute
- Developer Apeiron Biologics; BeiGene; Children's Cancer Research Institute; EUSA Pharma; Nagoya University; SIOPEN
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neuroblastoma
Most Recent Events
- 28 Jun 2023 BeiGene completes a phase I trial in (In infants, In adolescents, In adults, In the elderly) in China (IV) (NCT05373901)
- 02 Jun 2023 Updated efficacy data from the phase III SIOPEN trial in Neuroblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 07 Jun 2022 BeiGene initiates a phase I trial in (In infants, In adolescents, In adults, In the elderly) in China (IV) (NCT05373901)